Observational studyESC heart failure2026
Prognosis of tricuspid regurgitation after mitral transcatheter edge-to-edge repair: the EXPANDed studies.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTranscatheter therapies offer new treatment options for patients with both mitral regurgitation (MR) and tricuspid regurgitation (TR). However, the optimal treatment pathway in patients with combined MR and TR is not completely understood.
aimsThis analysis evaluated the natural TR progression after mitral transcatheter edge-to-edge repair (MTEER) with the MitraClip System in patients with MR and TR from the EXPANDed studies.
methodsEXPANDed is a pooled cohort from the EXPAND and EXPAND G4 studies. This study includes patients who had severe TR, achieved procedural success with MTEER, and received no direct TR intervention. Echocardiographic assessments were performed independently by echo core lab. Baseline characteristics, 1-year outcomes, and associations with TR improvement were reported based on 30-day TR severity following MTEER.
resultsOf those with evaluable TR data at 30 days (N = 160), 73% (N = 116) improved to ≤moderate TR, while 28% (N = 44) had ≥severe TR. The ≤moderate TR group had a lower prevalence of atrial fibrillation (68% vs 89%, P = .009), numerically lower LV ejection fraction (49% vs 56%, P = .07), and larger LV dimensions (LVEDV: 137.5 ± 73.4 vs 107.9 ± 44.8 ml, P = .01). TR reduction was sustained in 86% of ≤moderate TR patients, while 45% of ≥severe TR patients improved to ≤moderate at 1 year. In the ≤moderate TR group, significant and larger improvements in NYHA functional class (P < .0001) and KCCQ-OS score (Δ = + 30.6 ± 25.7, P < .0001) were observed through 1 year. One-year mortality was numerically lower in the ≤moderate TR group (12.4% vs 22.3%) though not statistically significant (HR = 1.92 [.77, 4.79], P = .16). Lower LVEF and larger baseline LV size were associated with TR improvement post-MTEER.
conclusionsEarly TR improvement to ≤moderate was observed in almost 3/4 of the population and was associated with significant symptomatic relief. Patients with both severe MR and TR, particularly those with LV dilation, may experience TR improvement following MTEER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.